Sunstar Butler today announced the availability of an easy-to-use 0.5cc syringe for dispensing PerioGlas® Synthetic Bone Graft Material, a unique bioactive bone grafting particulate. Proven in more than 700,000 cases worldwide, PerioGlas® is safe and biocompatible and bonds to both bone and soft tissue. PerioGlas® is clinically shown to regenerate bone as fast and as dense as demineralized freeze-dried bone allograft.
With better handling than autogenous bone and DFDBA, PerioGlas® eliminates the need for second surgical sites required for autografts, thus reducing the risk of infection and patient discomfort. PerioGlas® is more readily accepted by patients than animal-derived products, it and offers no risk of transgenic disease or rejection. PerioGlas also exhibits an antimicrobial effect on oral microorganisms.
PerioGlas® is indicated for a variety of osseous defects, including ridge augmentation, sinus elevation, extraction sites, cystectomies and apicoectomies, and periodontal and peri-implant defects.
Sunstar Butler and its parent company, Sunstar Inc., continue in a global partnership with dentistry in developing a better understanding of the potential links between oral health, general health and quality of life. One of the most trusted brands for more than 80 years, the company’s products are designed in consultation with dental professionals and are manufactured to the highest quality standards, assuring product excellence and patient satisfaction.